AR072652A1 - Composicion farmaceutica que comprende un polimero de amina reticulada. comprimido. metodo de preparacion. metodo para tratar la hiperfosfatemia. - Google Patents

Composicion farmaceutica que comprende un polimero de amina reticulada. comprimido. metodo de preparacion. metodo para tratar la hiperfosfatemia.

Info

Publication number
AR072652A1
AR072652A1 ARP080105441A ARP080105441A AR072652A1 AR 072652 A1 AR072652 A1 AR 072652A1 AR P080105441 A ARP080105441 A AR P080105441A AR P080105441 A ARP080105441 A AR P080105441A AR 072652 A1 AR072652 A1 AR 072652A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
particles
amine polymer
composition according
polymer
Prior art date
Application number
ARP080105441A
Other languages
English (en)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR072652A1 publication Critical patent/AR072652A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/08—Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/12—Macromolecular compounds
    • B01J41/14—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1: Una composicion farmacéutica que comprende un polímero amina reticulada caracterizada porque comprende: i) unidades de repeticion representadas por las siguientes Formula 1 y/o Formula 2: donde m es un numero entero de 0 a 2; n es un numero entero y cada R1, R2 y R3 representan en forma independiente hidrogeno; alquilo C1-6 sustituido o no sustituido, ramificado o no ramificado; alquilamino C1-6 sustituido o no sustituido, ramificado o no ramificado; X es un contraion aceptable para uso farmacéutico; y ii) un agente reticulante o residuo del mismo; donde dicho polímero de amina comprende partículas que tienen una distribucion de tamano de partículas seca donde más del 10% en vol. de las partículas tienen un tamano de partícula mayor que 500 microm. Reivindicacion 2: La composicion farmacéutica de acuerde con la reivindicacion 1 caracterizada porque m es 1 y cada R1. R2 y R3 representan en forma independiente hidrogeno. Reivindicacion 5: La composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 1-4, caracterizada porque el contraion principal para el polímero de amina reticulada es carbonato. Reivindicacion 9: La composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 1-7, caracterizada porque dichas partículas de polímero de amina reticulada son partículas agregadas curadas, cada una compuesta por más de 100 partículas constituyentes de polialilamina reticulada con 9,5-10% en peso de epiclorohidrina, o una sal aceptable para uso farmacéutico de la misma.
ARP080105441A 2007-12-14 2008-12-12 Composicion farmaceutica que comprende un polimero de amina reticulada. comprimido. metodo de preparacion. metodo para tratar la hiperfosfatemia. AR072652A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US601907P 2007-12-14 2007-12-14

Publications (1)

Publication Number Publication Date
AR072652A1 true AR072652A1 (es) 2010-09-15

Family

ID=40753579

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105441A AR072652A1 (es) 2007-12-14 2008-12-12 Composicion farmaceutica que comprende un polimero de amina reticulada. comprimido. metodo de preparacion. metodo para tratar la hiperfosfatemia.

Country Status (9)

Country Link
US (4) US20090155368A1 (es)
EP (1) EP2222313A4 (es)
JP (1) JP2011506448A (es)
AR (1) AR072652A1 (es)
PA (1) PA8807201A1 (es)
PE (1) PE20091331A1 (es)
TW (1) TW200930384A (es)
UY (1) UY31530A (es)
WO (1) WO2009078956A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142952A1 (en) * 2008-06-20 2011-06-16 Harris David J Pharmaceutical Compositions
WO2013064193A1 (en) * 2011-11-04 2013-05-10 Synthon Bv Pharmaceutical compositions comprising sevelamer
WO2013087237A1 (en) * 2011-12-13 2013-06-20 Synthon Bv Purification of sevelamer and related polyallylamines
WO2013087238A1 (en) * 2011-12-13 2013-06-20 Synthon Bv Preparation of sevelamer with reduced content of allylamine
CN102895204B (zh) * 2012-11-08 2014-12-31 南京生命能科技开发有限公司 一种用于制备片剂的碳酸司维拉姆原料药及其制备方法和应用
CN103864972A (zh) * 2012-12-10 2014-06-18 天津泰普药品科技发展有限公司 一种碳酸司维拉姆的制备方法
US9566299B2 (en) * 2013-02-08 2017-02-14 Wockhardt Limited Oral pharmaceutical composition of aliphatic amine polymer or salts thereof
EP3578185B1 (en) 2013-06-05 2020-08-05 Tricida Inc. Proton-binding polymers for oral administration
BR122021001914B1 (pt) 2014-12-10 2024-02-27 Tricida, Inc Processo para preparação de um polímero de amina reticulada
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
US11406661B2 (en) 2016-05-06 2022-08-09 Tricida, Inc. HCl-binding compositions for and methods of treating acid-base disorders
RU2722183C1 (ru) * 2016-10-20 2020-05-28 Колгейт-Палмолив Компани Противомикробные композиции для ухода за полостью рта или ее очистки и способы получения полимеров и покрытий, препятствующих прикреплению
KR101853260B1 (ko) * 2016-11-29 2018-06-14 주식회사 퍼슨 세벨라머 카보네이트의 제조방법
AU2017388956A1 (en) 2016-12-28 2019-07-11 Fujifilm Corporation Emulsion of nitrogen atom-containing polymer or salt thereof, production method therefor, and production method for particles
JP7018451B2 (ja) * 2017-10-16 2022-02-10 富士フイルム株式会社 高リン血症治療剤および粒子
WO2019078197A1 (ja) * 2017-10-16 2019-04-25 富士フイルム株式会社 高リン血症治療剤
EP3703706A4 (en) 2017-11-03 2022-04-27 Tricida Inc. COMPOSITIONS AND METHOD FOR TREATING ACID-BASE DISORDERS
CN109125273B (zh) * 2018-09-28 2020-10-09 北京市中关村医院 一种磷结合剂及其制备方法和用途
CN112972407A (zh) * 2019-12-18 2021-06-18 南京恒生制药有限公司 一种碳酸司维拉姆片剂组合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US6423754B1 (en) * 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
TW568788B (en) * 1998-10-12 2004-01-01 Chugai Pharmaceutical Co Ltd Polymer combining with phosphoric acid and preparation containing the same
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
PT1924246E (pt) * 2005-09-15 2016-02-10 Genzyme Corp Formulação sachê para polímeros com funcionalidade amina

Also Published As

Publication number Publication date
US20090155368A1 (en) 2009-06-18
EP2222313A4 (en) 2011-02-16
UY31530A (es) 2009-12-14
PA8807201A1 (es) 2009-07-23
JP2011506448A (ja) 2011-03-03
WO2009078956A1 (en) 2009-06-25
US20190240252A1 (en) 2019-08-08
PE20091331A1 (es) 2009-09-18
US20140322319A1 (en) 2014-10-30
TW200930384A (en) 2009-07-16
EP2222313A1 (en) 2010-09-01
US20160158275A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
AR072652A1 (es) Composicion farmaceutica que comprende un polimero de amina reticulada. comprimido. metodo de preparacion. metodo para tratar la hiperfosfatemia.
PH12021550701A1 (en) Ionizable amine lipids
BR112012006635B8 (pt) composição que compreende partículas de tamanho micro de fosfato de cálcio uniformes, rígidas, esféricas, nanoporosas e método para combinar e separar o solvente não aquoso das referidas partículas
BR112013010515A2 (pt) partículas de grafeno revestidas de diamante, composições e estruturas intermédias compreendendo o mesmo e os métodos de formação de poli cristalinos de partículas de diamante grafeno-revestido e compactos
GB201020193D0 (en) Glucan compositions
AR094583A1 (es) Composiciones que incluyen agentes para conferir carácter hidrofóbico y estabilizante y métodos para elaborar y usar los mismos
AR081370A1 (es) Emulsiones con alto contenido de solvente
TR201906255T4 (tr) Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar.
PE20041036A1 (es) Mezcla para mejorar resistencias en composiciones cementosas
AR054637A1 (es) Aerosoles y composiciones hemostaticas
MX2013002830A (es) Composicion que contiene un insecticida de piripiropeno y un adyuvante.
RS51271B (sr) Čvrsta farmaceutska kompozicija koja sadrži donepezil hidrohlorid
BR112015014065A2 (pt) éter de celulose esterificado, composição, dispersão sólida, forma de dosagem e invólucro de cápsula
MX2018013935A (es) Composiciones alcalinas y neutrales de limpieza, sanitizacion y desinfeccion con nebulizacion reducida a traves del uso de polimeros de emulsion de agua en aceite de alto peso molecular.
AR081539A1 (es) Composicion a base de fexofenadina y procedimiento de preparacion, sobre o comprimido, uso de la composicion
BR112012031495A2 (pt) emulsões acrílicas intumescíveis alcalinas livres de tensoativo, seu uso em formulações aquosas e formulações contendo-as
BR112017018367A2 (pt) gelificação de éteres de celulose esterificados
CL2018000810A1 (es) Composiciones de poliolefina con mejoradas propiedades mecánicas y de barrera
AR092806A1 (es) Formulacion concentrada liquida que contiene un insecticida de piripiropeno i
MY183106A (en) Fine dry particulate retinoid active agent compostions and topical formulations including the same
BR112015008189A2 (pt) composição, processo para sua preparação e compósito
MX2014014527A (es) Composiciones para demarcacion del pavimento.
WO2013085897A3 (en) A method for reducing agglomeration in gypsum plaster or filling compositions comprising cellulose ether
BR112019001841A2 (pt) composição para cuidados pessoais.
PE20180599A1 (es) Construcciones de calicheamicina y sus metodos de uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure